Zimmer Biomet announced robust financial results for the fourth quarter and full-year 2025, with net sales increasing by 10.9% on a reported basis to $2.244 billion. Adjusted diluted earnings per share rose by 4.8% to $2.42, reflecting strong operational performance and strategic execution.

Zimmer Biomet delivered solid Q3 results with $2.0B in revenue and strong adjusted EPS of $1.90. Net income reached $230.9M. U.S. sales were the main growth driver, while Latin America and parts of Europe saw softness.

Zimmer Biomet delivered solid Q2 2025 results with $2.077 billion in revenue and $152.8 million in net earnings. Growth was driven by increased sales in Hips and S.E.T. segments, especially in the U.S., as well as strategic initiatives including a major acquisition.

Zimmer Biomet delivered strong Q1 results with revenue of $1.91B and adjusted EPS of $1.81, supported by U.S. hip portfolio momentum and the Paragon 28 acquisition.

Zimmer Biomet announced Q4 2024 net sales of $2.023 billion, a 4.3% increase, with diluted earnings per share at $1.20 and adjusted diluted earnings per share at $2.31. Full-year net sales reached $7.679 billion, up 3.8%, with diluted earnings per share at $4.43 and adjusted diluted earnings per share at $8.00. The company also provided full-year 2025 financial guidance and announced an agreement to acquire Paragon 28.

Zimmer Biomet reported a strong third quarter with net sales of $1.824 billion, a 4.0% increase over the prior year. Diluted earnings per share were $1.23, and adjusted diluted earnings per share were $1.74. The company has updated its 2024 financial guidance, reducing and narrowing the range for the full-year outlook.

Zimmer Biomet reported a strong Q2, exceeding expectations for both revenue and earnings. Net sales increased by 3.9% to $1.942 billion, and adjusted diluted earnings per share were $2.01. The company has updated its 2024 reported revenue guidance due to currency expectations and reaffirmed its constant currency revenue growth and adjusted EPS guidance.

Zimmer Biomet reported first quarter net sales of $1.889 billion, a 3.2% increase over the prior year, and a 4.4% increase on a constant currency basis. Diluted earnings per share were $0.84, and adjusted diluted earnings per share were $1.94. The company reiterated its full-year 2024 financial guidance.

Zimmer Biomet reported a strong finish to 2023 with Q4 net sales increasing by 6.3% to $1.940 billion and diluted earnings per share at $2.01. The company's full-year net sales reached $7.394 billion, a 6.5% increase, with diluted earnings per share at $4.88. The company is providing full-year 2024 financial guidance.

Zimmer Biomet announced third quarter net sales of $1.754 billion, an increase of 5.0% over the prior year period, and an increase of 4.7% on a constant currency basis. Diluted earnings per share were $0.77 for the third quarter, and adjusted diluted earnings per share were $1.65.

Zimmer Biomet announced its second quarter 2023 financial results, reporting net sales of $1.870 billion, a 4.9% increase over the prior year, and a 6.0% increase on a constant currency basis. Net earnings were $209.6 million, with diluted earnings per share at $1.00. The company has raised its 2023 financial guidance based on its business performance and innovation pipeline.

Zimmer Biomet announced first quarter net sales of $1.831 billion, a 10.1% increase year-over-year, and an adjusted diluted earnings per share of $1.89. The company has raised and tightened its 2023 financial guidance.

Zimmer Biomet reported a 2.7% increase in fourth-quarter net sales from continuing operations, reaching $1.825 billion, with an 8.3% increase on a constant currency basis. The diluted loss per share was $0.62, while adjusted diluted earnings per share were $1.88. The company is providing full-year 2023 financial guidance.

Zimmer Biomet's third quarter net sales were $1.670 billion, a decrease of 0.9% over the prior year, but increased 5.0% on a constant currency basis. Net earnings were $194.0 million, or $333.1 million on an adjusted basis. Diluted earnings per share were $0.92, and adjusted diluted earnings per share were $1.58.

Zimmer Biomet's Q2 2022 performance exceeded internal expectations due to a stronger COVID recovery and effective execution. Net sales reached $1.782 billion, a 1.0% increase, and adjusted diluted EPS was $1.82. The company updated its 2022 financial guidance, raising the full-year outlook.

Zimmer Biomet's Q1 2022 net sales from continuing operations were $1.663 billion, a 3.9% increase over the prior year and a 6.8% increase on a constant currency basis. Diluted earnings per share from continuing operations were $0.35, and adjusted diluted earnings per share were $1.61. The company updated its 2022 financial guidance, raising and tightening the range for the full-year outlook.

Zimmer Biomet reported a decrease in net sales for the fourth quarter of 2021, alongside a net loss, although adjusted earnings per share showed a positive figure. The company's performance was impacted by the ongoing COVID-19 pandemic and China's volume-based procurement.

Zimmer Biomet reported third quarter net sales of $1.924 billion, a decrease of 0.3% from the prior year period. Diluted earnings per share were $0.69 for the third quarter, and adjusted diluted earnings per share were $1.81. The company updated its full-year 2021 financial guidance, reducing and narrowing its previous projected ranges for revenue growth, adjusted operating profit margin and adjusted diluted EPS.

Zimmer Biomet's second quarter net sales were $2.027 billion, an increase of 65.3% over the prior year period, and an increase of 60.7% on a constant currency basis. Second quarter 2021 net sales increased 1.9% when compared to the pre-pandemic second quarter 2019, and were flat on a constant currency basis. Net earnings for the second quarter of 2021 were $141.9 million, or $400.5 million on an adjusted basis. Diluted earnings per share were $0.67 for the second quarter and adjusted diluted earnings per share were $1.90.

Zimmer Biomet reported a stronger than anticipated first quarter, driven by signs of the pandemic subsiding in many regions due to accelerated vaccine rollouts. Net sales increased by 3.6% to $1.847 billion, and adjusted diluted earnings per share increased by 0.6% to $1.71.

Zimmer Biomet reported Q4 net sales of $2.085 billion, a decrease of 1.9% compared to the prior year. Diluted earnings per share were $1.59, while adjusted diluted earnings per share were $2.11. The company also announced its intention to spin off its Spine and Dental businesses.

Zimmer Biomet reported third quarter net sales of $1.929 billion, a 2.0% increase over the prior year, and diluted earnings per share of $1.16. Adjusted diluted earnings per share were $1.81, a 2.3% increase over the prior year.

Zimmer Biomet's second quarter net sales were $1.226 billion, a decrease of 38.3% from the prior year period. The company reported a net loss of $206.6 million, with a diluted loss per share of $1.00. Adjusted diluted earnings per share were $0.05, a decrease of 97.4% from the prior year period.

Zimmer Biomet reported a 9.7% decrease in net sales to $1.784 billion for the first quarter of 2020. The company experienced a net loss of $509 million, which includes goodwill impairment, but net earnings on an adjusted basis were $354 million. The COVID-19 pandemic significantly impacted elective procedure volumes, negatively affecting the company's performance.

Zimmer Biomet announced fourth quarter net sales of $2.126 billion, a 2.6% increase over the prior year period, and diluted EPS of $1.54. Adjusted diluted EPS were $2.30, a 5.5% increase over the prior year period. The company provided full-year 2020 revenue growth guidance of 2.5% to 3.5%.